Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Rat|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||A peptide corresponding to the amino acids 20-37 TQETFPPKYLHYDEETSH of human OPG was used as immunogen for this antibody.|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||1:10-1:500|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:500|
|Western Blot (WB)||1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: Daudi.
Osteoprotegerin (OPG) is a secretory glycoprotein belonging to TNF receptor (TNFR) superfamily (1). As the name implies, it protects bone. Unlike other TNFRs it lacks a transmembrane domain and lacks any apparent cell associated signals. OPG consists of 401 amino acid with molecular mass of approximately 55 kD as a monomer and 110 kD as a disulfide-linked dimer. High levels of OPG mRNA has been detected in lung, heart, kidney, and placenta1. Recombinant OPG blocks osteoclastogenesis in vitro and increases bone density in vivo. Targeted deletion of OPG in mice results in severe early-onset of osteoporosity. These mice also exhibit increase in vascular calcification in the aorta and renal arteries suggesting that it may also play a role in degenerative arterial disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
OCIF; OPG; osteoclastogenesis inhibitory factor; osteoprotegerin; TR1; tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily, member 11b
OCIF; OPG; PDB5; TNFRSF11B; TR1